Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington’s disease models

Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington’s disease models

Chemically modified siRNAs distinguish between mutant and normal huntingtin based on a single nucleotide difference and lower mutant huntingtin specifically in patient derived cells and in a mouse model of Huntington’s disease.

Bibliographic Details
Main Authors:	Faith Conroy, Rachael Miller, Julia F. Alterman, Matthew R. Hassler, Dimas Echeverria, Bruno M. D. C. Godinho, Emily G. Knox, Ellen Sapp, Jaquelyn Sousa, Ken Yamada, Farah Mahmood, Adel Boudi, Kimberly Kegel-Gleason, Marian DiFiglia, Neil Aronin, Anastasia Khvorova, Edith L. Pfister
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-10-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-022-33061-x

Similar Items

Protein changes in synaptosomes of Huntington's disease knock-in mice are dependent on age and brain region
by: Ellen Sapp, et al.
Published: (2020-07-01)

Disposition of Proteins and Lipids in Synaptic Membrane Compartments Is Altered in Q175/Q7 Huntington’s Disease Mouse Striatum
by: Maria Iuliano, et al.
Published: (2021-03-01)

Early whole-body mutant huntingtin lowering averts changes in proteins and lipids important for synapse function and white matter maintenance in the LacQ140 mouse model
by: Kai Shing, et al.
Published: (2023-10-01)

Disruption of Rab11 activity in a knock-in mouse model of Huntington's disease
by: Xueyi Li, et al.
Published: (2009-11-01)

2′-O-Methyl at 20-mer Guide Strand 3′ Termini May Negatively Affect Target Silencing Activity of Fully Chemically Modified siRNA
by: Sarah M. Davis, et al.
Published: (2020-09-01)

Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain
by: Mehran Nikan, et al.
Published: (2016-01-01)

Huntingtin associates with the actin cytoskeleton and α-actinin isoforms to influence stimulus dependent morphology changes.
by: Adelaide Tousley, et al.
Published: (2019-01-01)

PK-modifying anchors significantly alter clearance kinetics, tissue distribution, and efficacy of therapeutics siRNAs
by: Bruno M.D.C. Godinho, et al.
Published: (2022-09-01)

Single intravitreal administration of a tetravalent siRNA exhibits robust and efficient gene silencing in mouse and pig photoreceptors
by: Shun-Yun Cheng, et al.
Published: (2024-03-01)

Alterations in mRNA 3′ UTR Isoform Abundance Accompany Gene Expression Changes in Human Huntington’s Disease Brains
by: Lindsay Romo, et al.
Published: (2017-09-01)

Serum Deprivation of Mesenchymal Stem Cells Improves Exosome Activity and Alters Lipid and Protein Composition
by: Reka Agnes Haraszti, et al.
Published: (2019-06-01)

Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1
by: Sarah M. Davis, et al.
Published: (2022-09-01)

Hippo Signaling Pathway Dysregulation in Human Huntington’s Disease Brain and Neuronal Stem Cells
by: Kaly A. Mueller, et al.
Published: (2018-07-01)

Cell Type Impacts Accessibility of mRNA to Silencing by RNA Interference
by: Chantal M. Ferguson, et al.
Published: (2020-09-01)

Kalirin Interacts with TRAPP and Regulates Rab11 and Endosomal Recycling
by: Xiaolong Wang, et al.
Published: (2020-05-01)

RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA
by: Sebastian Aguiar, et al.
Published: (2017-11-01)

Safe and Efficient Silencing with a Pol II, but Not a Pol lII, Promoter Expressing an Artificial miRNA Targeting Human Huntingtin
by: Edith L. Pfister, et al.
Published: (2017-06-01)

Dendritic amphiphilic siRNA: Selective albumin binding, in vivo efficacy, and low toxicity
by: Hassan H. Fakih, et al.
Published: (2023-12-01)

Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the httQ140/Q140 mouse model of Huntington's disease
by: Robyn L. McAdam, et al.
Published: (2020-02-01)

Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing
by: Aamir Mir, et al.
Published: (2018-07-01)

Asymmetric trichotomous partitioning overcomes dataset limitations in building machine learning models for predicting siRNA efficacy
by: Kathryn R. Monopoli, et al.
Published: (2023-09-01)

Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors
by: Betschart Claudia, et al.
Published: (2010-12-01)

The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease
by: Frentzel Stefan, et al.
Published: (2010-06-01)

Pressure Injuries in Nursing Homes: Investigating Racial/Ethnic Differences Using National Data
by: Lara Dhingra, et al.
Published: (2023-10-01)

Designing siRNA that distinguish between genes that differ by a single nucleotide.
by: Dianne S Schwarz, et al.
Published: (2006-09-01)

Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin
by: Qi Tang, et al.
Published: (2023-11-01)

A era dos medicamentos de ARN interferência: o panorama clínico dos fármacos para silenciamento génico
by: Bruno M. D. C. Godinho, et al.
Published: (2022-07-01)

Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi.
by: Yusuke Ohnishi, et al.
Published: (2008-01-01)

Development of allele-specific therapeutic siRNA in Meesmann epithelial corneal dystrophy.
by: Haihui Liao, et al.
Published: (2011-01-01)

Haplotype-specific insertion-deletion variations for allele-specific targeting in Huntington's disease
by: Jun Wan Shin, et al.
Published: (2022-06-01)

Huntington's "Gap"
by: Ricardo Lagorio
Published: (2017-11-01)

Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts
by: Kyle D. Fink Ph.D, et al.
Published: (2016-04-01)

Expanding the genetics of huntingtonism.
by: Feigin, A, et al.
Published: (2014)

Anaesthesia and Huntington′s chorea
by: Anurag Yadava, et al.
Published: (2006-01-01)

Huntington Disease in Asia
by: Miao Xu, et al.
Published: (2015-01-01)

Juvenile Huntington’s disease
by: G. E. Rudenskaya, et al.
Published: (2017-02-01)

Where should siRNAs go: applicable organs for siRNA drugs
by: Insook Ahn, et al.
Published: (2023-07-01)

Development of siRNA-probes for studying intracellular trafficking of siRNA nanoparticles
by: Alabi, Christopher A., et al.
Published: (2014)

Antibody–siRNA conjugates (ARC): Emerging siRNA drug formulation
by: Weiran Cao, et al.
Published: (2022-09-01)

Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition
by: Alexey Berezhnoy, et al.
Published: (2012-01-01)